<p>LeMaitre Vascular, Inc.（纳斯达克代码：LMAT - 获取免费报告）的股票在目前覆盖该公司的八位分析师中获得了 “适度买入” 的共识评级，MarketBeat Ratings 报告称。四位研究分析师对该股票给予了持有推荐，四位则给予了买入推荐。在过去一年中，对该股票发布评级的分析师的平均一年目标价为 100.20 美元。</p>
<p>获取 <strong>LeMaitre Vascular</strong> 的提醒：</p>
<p>LMAT 最近成为多份分析师报告的主题。Cantor Fitzgerald 在 11 月 10 日的报告中重申了 “中性” 评级，并将 LeMaitre Vascular 的目标价设定为 95.00 美元。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 LeMaitre Vascular 的 “买入（b-）” 评级。Wells Fargo &amp; Company 在 11 月 7 日的研究报告中将 LeMaitre Vascular 的目标价从 97.00 美元下调至 93.00 美元，并对该股票设定了 “等权重” 评级。Wall Street Zen 在 12 月 6 日的报告中将 LeMaitre Vascular 的评级从 “买入” 下调至 “持有”。最后，Roth Mkm 在 11 月 5 日的报告中重申了 “买入” 评级，并对 LeMaitre Vascular 的股票发布了 108.00 美元的目标价。</p>
<p><strong>获取我们最新的 LeMaitre Vascular 股票分析</strong></p>
<h2>LeMaitre Vascular 上涨 0.5%</h2>
<p>LMAT 周五开盘价为 87.42 美元。该公司的市值为 19.8 亿美元，市盈率为 37.68，市盈增长比率为 1.93，贝塔值为 0.72。公司的 50 日简单移动平均线为 84.53 美元，200 日简单移动平均线为 87.66 美元。LeMaitre Vascular 的 1 年最低价为 71.42 美元，1 年最高价为 105.55 美元。该公司的债务股本比为 0.44，流动比率为 13.58，速动比率为 11.45。</p>
<p>LeMaitre Vascular（纳斯达克代码：LMAT - 获取免费报告）最近于 11 月 6 日发布了季度财报。这家医疗器械供应商报告本季度每股收益为 0.62 美元，超出市场共识预期的 0.57 美元，超出幅度为 0.05 美元。该公司本季度的收入为 6105 万美元，而分析师预期为 6218 万美元。LeMaitre Vascular 的股本回报率为 14.06%，净利润率为 22.14%。该公司的季度收入同比增长 11.4%。去年同期，该公司每股收益为 0.49 美元。分析师预计 LeMaitre Vascular 在当前财政年度将发布 1.94 美元的每股收益。</p>
<h2>对 LeMaitre Vascular 的对冲基金看法</h2>
<p>对冲基金最近对该股票的持仓进行了调整。Parkside Financial Bank &amp; Trust 在第二季度将其在 LeMaitre Vascular 的持股增加了 1913.3%。Parkside Financial Bank &amp; Trust 目前拥有 302 股该医疗器械供应商的股票，价值 25,000 美元，此前在上个季度购买了 287 股。Cornerstone Planning Group LLC 在第三季度将其在 LeMaitre Vascular 的持仓增加了 534.0%。Cornerstone Planning Group LLC 目前拥有 336 股该医疗器械供应商的股票，价值 30,000 美元，此前在该期间购买了 283 股。MAI Capital Management 在第三季度收购了 LeMaitre Vascular 的新股份，价值 38,000 美元。First Horizon Corp 在第三季度购买了 LeMaitre Vascular 的新股份，价值 39,000 美元。最后，Geneos Wealth Management Inc.在第一季度将其在 LeMaitre Vascular 的持股增加了 250.3%。Geneos Wealth Management Inc.目前拥有 557 股该医疗器械供应商的股票，价值 47,000 美元，此前在上个季度增加了 398 股。对冲基金和其他机构投资者持有该公司 84.64% 的股份。</p>
<h2>LeMaitre Vascular 公司简介</h2>
<p>（获取免费报告）</p>
<p>LeMaitre Vascular, Inc 是一家专注于开发、制造和营销用于治疗外周血管疾病的专业医疗设备公司。公司总部位于马萨诸塞州伯灵顿，提供包括广泛的血管外科器械、移植物、补片、导管和栓塞保护装置在内的产品组合。LeMaitre 的产品线涵盖动脉重建、血管内修复和血管通路等关键领域，满足心血管外科医生和介入专家的需求。</p>
<p>该公司成立于 1983 年，由 George D.创立。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 LeMaitre Vascular 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 LeMaitre Vascular 吗？</h2>
<p>在你考虑 LeMaitre Vascular 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 LeMaitre Vascular 并不在名单上。</p>
<p>虽然 LeMaitre Vascular 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

勒梅特微管医疗

<p>LeMaitre Vascular, Inc.（纳斯达克代码：LMAT）获得了八位分析师的 “适度买入” 共识评级。四位分析师建议持有该股票，而四位分析师建议买入。平均一年期目标价为 100.20 美元。最近的报告包括 Cantor Fitzgerald 的中性评级，目标价为 95.00 美元，以及 Roth Mkm 的买入评级，目标价为 108.00 美元。该公司报告每股收益为 0.62 美元，超出预期，收入为 6105 万美元，同比增长 11.4%。对冲基金持有该股票的 84.64%，显示出强烈的机构兴趣</p>

<p>Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have received a consensus rating of &#34;Moderate Buy&#34; from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $100.20.</p>
<div class="lb-trans"><p>LeMaitre Vascular, Inc.（纳斯达克代码：LMAT - 获取免费报告）的股票在目前覆盖该公司的八位分析师中获得了 “适度买入” 的共识评级，MarketBeat Ratings 报告称。四位研究分析师对该股票给予了持有推荐，四位则给予了买入推荐。在过去一年中，对该股票发布评级的分析师的平均一年目标价为 100.20 美元。</p>
</div><p>Get <strong>LeMaitre Vascular</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>LeMaitre Vascular</strong> 的提醒：</p>
</div><p>LMAT has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated a &#34;neutral&#34; rating and set a $95.00 price target on shares of LeMaitre Vascular in a report on Monday, November 10th. Weiss Ratings reissued a &#34;buy (b-)&#34; rating on shares of LeMaitre Vascular in a research note on Monday, December 29th. Wells Fargo &amp; Company reduced their target price on LeMaitre Vascular from $97.00 to $93.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Friday, November 7th. Wall Street Zen cut LeMaitre Vascular from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th. Finally, Roth Mkm restated a &#34;buy&#34; rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th.</p>
<div class="lb-trans"><p>LMAT 最近成为多份分析师报告的主题。Cantor Fitzgerald 在 11 月 10 日的报告中重申了 “中性” 评级，并将 LeMaitre Vascular 的目标价设定为 95.00 美元。Weiss Ratings 在 12 月 29 日的研究报告中重新发布了对 LeMaitre Vascular 的 “买入（b-）” 评级。Wells Fargo &amp; Company 在 11 月 7 日的研究报告中将 LeMaitre Vascular 的目标价从 97.00 美元下调至 93.00 美元，并对该股票设定了 “等权重” 评级。Wall Street Zen 在 12 月 6 日的报告中将 LeMaitre Vascular 的评级从 “买入” 下调至 “持有”。最后，Roth Mkm 在 11 月 5 日的报告中重申了 “买入” 评级，并对 LeMaitre Vascular 的股票发布了 108.00 美元的目标价。</p>
</div><p><strong>Get Our Latest Stock Analysis on LeMaitre Vascular</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 LeMaitre Vascular 股票分析</strong></p>
</div><h2>LeMaitre Vascular Trading Up 0.5%</h2>
<div class="lb-trans"><h2>LeMaitre Vascular 上涨 0.5%</h2>
</div><p>LMAT opened at $87.42 on Friday. The firm has a market capitalization of $1.98 billion, a price-to-earnings ratio of 37.68, a price-to-earnings-growth ratio of 1.93 and a beta of 0.72. The company's 50 day simple moving average is $84.53 and its two-hundred day simple moving average is $87.66. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $105.55. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45.</p>
<div class="lb-trans"><p>LMAT 周五开盘价为 87.42 美元。该公司的市值为 19.8 亿美元，市盈率为 37.68，市盈增长比率为 1.93，贝塔值为 0.72。公司的 50 日简单移动平均线为 84.53 美元，200 日简单移动平均线为 87.66 美元。LeMaitre Vascular 的 1 年最低价为 71.42 美元，1 年最高价为 105.55 美元。该公司的债务股本比为 0.44，流动比率为 13.58，速动比率为 11.45。</p>
</div><p>LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The firm had revenue of $61.05 million during the quarter, compared to analysts' expectations of $62.18 million. LeMaitre Vascular had a return on equity of 14.06% and a net margin of 22.14%.The business's revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 earnings per share. Analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>LeMaitre Vascular（纳斯达克代码：LMAT - 获取免费报告）最近于 11 月 6 日发布了季度财报。这家医疗器械供应商报告本季度每股收益为 0.62 美元，超出市场共识预期的 0.57 美元，超出幅度为 0.05 美元。该公司本季度的收入为 6105 万美元，而分析师预期为 6218 万美元。LeMaitre Vascular 的股本回报率为 14.06%，净利润率为 22.14%。该公司的季度收入同比增长 11.4%。去年同期，该公司每股收益为 0.49 美元。分析师预计 LeMaitre Vascular 在当前财政年度将发布 1.94 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On LeMaitre Vascular</h2>
<div class="lb-trans"><h2>对 LeMaitre Vascular 的对冲基金看法</h2>
</div><p>Hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank &amp; Trust increased its holdings in LeMaitre Vascular by 1,913.3% in the 2nd quarter. Parkside Financial Bank &amp; Trust now owns 302 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 287 shares during the last quarter. Cornerstone Planning Group LLC boosted its position in shares of LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier's stock worth $30,000 after buying an additional 283 shares during the period. MAI Capital Management acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at $38,000. First Horizon Corp purchased a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at $39,000. Finally, Geneos Wealth Management Inc. lifted its stake in LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 398 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.</p>
<div class="lb-trans"><p>对冲基金最近对该股票的持仓进行了调整。Parkside Financial Bank &amp; Trust 在第二季度将其在 LeMaitre Vascular 的持股增加了 1913.3%。Parkside Financial Bank &amp; Trust 目前拥有 302 股该医疗器械供应商的股票，价值 25,000 美元，此前在上个季度购买了 287 股。Cornerstone Planning Group LLC 在第三季度将其在 LeMaitre Vascular 的持仓增加了 534.0%。Cornerstone Planning Group LLC 目前拥有 336 股该医疗器械供应商的股票，价值 30,000 美元，此前在该期间购买了 283 股。MAI Capital Management 在第三季度收购了 LeMaitre Vascular 的新股份，价值 38,000 美元。First Horizon Corp 在第三季度购买了 LeMaitre Vascular 的新股份，价值 39,000 美元。最后，Geneos Wealth Management Inc.在第一季度将其在 LeMaitre Vascular 的持股增加了 250.3%。Geneos Wealth Management Inc.目前拥有 557 股该医疗器械供应商的股票，价值 47,000 美元，此前在上个季度增加了 398 股。对冲基金和其他机构投资者持有该公司 84.64% 的股份。</p>
</div><h2>LeMaitre Vascular Company Profile</h2>
<div class="lb-trans"><h2>LeMaitre Vascular 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.</p>
<div class="lb-trans"><p>LeMaitre Vascular, Inc 是一家专注于开发、制造和营销用于治疗外周血管疾病的专业医疗设备公司。公司总部位于马萨诸塞州伯灵顿，提供包括广泛的血管外科器械、移植物、补片、导管和栓塞保护装置在内的产品组合。LeMaitre 的产品线涵盖动脉重建、血管内修复和血管通路等关键领域，满足心血管外科医生和介入专家的需求。</p>
</div><p>Founded in 1983 by George D.</p>
<div class="lb-trans"><p>该公司成立于 1983 年，由 George D.创立。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than LeMaitre Vascular</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The day the gold market broke</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>He just nailed another gold prediction …</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 LeMaitre Vascular 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>黄金市场崩溃的那一天</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>你的银行账户不再安全</li>
<li>他刚刚准确预测了另一个黄金走势……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LMAT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LeMaitre Vascular Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LeMaitre Vascular 吗？</h2>
</div><p>Before you consider LeMaitre Vascular, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 LeMaitre Vascular 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 LeMaitre Vascular 并不在名单上。</p>
</div><p>While LeMaitre Vascular currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LeMaitre Vascular 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

勒梅特微管医疗公司（NASDAQ:LMAT）被券商一致给予 “适度买入” 评级